
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.
Read more
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.
Read more